Do Drug Cost Containment Measures in India Increase Affordability of Cancer Drugs? Evidence from Spending on and Cost of Cancer Medicines (Record no. 134298)

MARC details
000 -LEADER
fixed length control field 01971nam a2200229Ia 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 241008s9999||||xx |||||||||||||| ||und||
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0972-0634
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name George, Sobin
245 #0 - TITLE STATEMENT
Title Do Drug Cost Containment Measures in India Increase Affordability of Cancer Drugs? Evidence from Spending on and Cost of Cancer Medicines
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Journal of Health Management
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2024
300 ## - PHYSICAL DESCRIPTION
Extent 486-495
520 ## - SUMMARY, ETC.
Abstract The article examines the drug pricing policy and cost containment measures in India by drawing on the data of spending on and price variations of cancer drugs. Results show that medicines held the highest share in the out-of-pocket (OOP) cancer medical expenditure in private and public sectors, and it was more pronounced for private sector and in outpatient care. Medicine expenditure has a positive and significant causal association to OOP medical expenditure of cancer patients even when other medical costs, type of care and socio-economic backgrounds are controlled for. Further, there were significant price variations for recently approved anticancer medicines across brands, which are under and outside price control. The results confirm the ineffectiveness of price control measures for cancer drugs under market-based pricing policy and the inadequacy of existing risk protection measures in India. This calls for the adoption of appropriate cost containment measures, which include expanding the scope of all forms, types and severities of cancer and anticancer medications under health insurance and adoption of a uniform treatment protocol across private and public sectors.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Anticancer Medications
9 (RLIN) 122546
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cancer Drug
9 (RLIN) 122547
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cost of Cancer Medicines
9 (RLIN) 122548
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Pricing Policy
9 (RLIN) 122549
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Cost
9 (RLIN) 122550
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Balachandran, Arun
9 (RLIN) 117141
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name K N, Anushree
9 (RLIN) 122551
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1177/09720634241246940">https://doi.org/10.1177/09720634241246940</a>
999 ## - SYSTEM CONTROL NUMBERS (KOHA)
Koha biblionumber 134298
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Date acquired Serial Enumeration / chronology Total Checkouts Barcode Date last seen Price effective from Koha item type
        Dr VKRV Rao Library Dr VKRV Rao Library 08/10/2024 Vol. 26, No. 3   AI582 08/10/2024 08/10/2024 Article Index